Tempus AI reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised its full-year guidance, pointing to continued demand for its AI-enabled diagnostic platform. Diagnostics revenue rose 35% to $261.1 million, with oncology volumes up 28% and minimal residual disease (MRD) testing volume growing roughly sixfold to about 6,500 tests.